Indian pharmaceutical giants Torrent Pharmaceuticals Limited and Zydus Lifesciences Limited have entered a licensing and supply agreement to jointly market Saroglitazar Mg in India.

This breakthrough drug, approved by India's Drugs Controller General, targets Non-Alcoholic Steato Hepatitis (NASH) and Non-Alcoholic Fatty Liver Disease (NAFLD).

As the only approved treatment for NASH and NAFLD in India, Saroglitazar Mg is poised to play a pivotal role in managing these liver disorders.

Torrent gains semi-exclusive rights to co-market the drug as VORXAR, while Zydus will continue marketing it as Lipaglyn and Bilypsa. The partnership involves upfront licensing fees and milestone payments tied to predefined achievements.

Zydus Lifesciences' Managing Director, Sharvil Patel, expressed that the collaboration reflects their long-term vision of expanding the drug's reach to address unmet healthcare needs. Aman Mehta, Director of Torrent Pharmaceuticals Ltd., highlighted the significance of Saroglitazar Mg in advancing their gastroenterology franchise and addressing emerging patient needs.

Saroglitazar Mg, the first approved drug for NASH and NAFLD globally, addresses a crucial gap in treatment options. Its unique properties have benefited over 1.5 million patients since its launch in 2013. In 2020, it received approval for treating Type 2 diabetes mellitus, showcasing its expanding applications. The drug's effectiveness extends to a substantial portion of India's adult population affected by NAFLD, offering a promising solution from fatty liver to severe liver issues.